Patients can expect comprehensive initial evaluations that include detailed medical histories, body composition analysis, and laboratory work to identify factors like insulin resistance or thyroid dysfunction
During the opening lecture at the International Conference on Advanced Technologies & Treatments for Diabetes, Melanie Davies, CBE, MB, ChB, MD, FRCP, FRCGP, professor of diabetes medicine at the University of Leicester and an honorary consultant diabetologist at the University Hospitals of Leicester NHS Trust, reviewed how GLP-1 receptor agonists such as semaglutide (Ozempic/Wegovy, Novo Nordisk) have changed the way providers approach the treatment of type 2 diabetes and obesity and discussed some of the medications that combine GLP-1 with other molecules
High insulin is very, very bad
The cardiovascular system and its pathophysiology are complex and GLP-1 asserts its effects through numerous pathways